1623 Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

1623 Capital’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5,789	Closed	-$240K	–	41
2022 Q3	$240K	Sell	5,789 -1,442	-20%	-$74.1K	0.15%	43
2022 Q2	$431K	Buy	7,231 +3,187	+79%	+$196K	0.27%	33
2022 Q1	$294K	Sell	4,044 -633	-14%	-$44K	0.15%	47
2021 Q4	$393K	Hold	4,677	–	–	0.15%	56
2021 Q3	$422K	Buy	4,677 +900	+24%	+$81.3K	0.16%	56
2021 Q2	$360K	Buy	3,777 +825	+28%	+$86K	0.14%	62
2021 Q1	$336K	Buy	+2,952	New	+$402K	0.14%	45

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

1623 Capital's RARE Position: Q4 2022 in Review

1623 Capital sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2022, closing a stake of 5,789 shares — an estimated $240K sold.

1623 Capital first reported a position in RARE in Q1 2021 and held it in 7 quarters. The position peaked at $431K in Q2 2022. 227 funds tracked by Wall St. Rank hold RARE as of Q4 2022.

1623 Capital reported no remaining Ultragenyx Pharmaceutical position as of Q4 2022 after selling out during the quarter.
1623 Capital sold 5,789 Ultragenyx Pharmaceutical shares in Q4 2022, an estimated $240K.
1623 Capital first reported a position in Ultragenyx Pharmaceutical in Q1 2021 and held it in 7 quarters.
1623 Capital's Ultragenyx Pharmaceutical position peaked at $431K in Q2 2022.
227 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2022.

Based on 1623 Capital's 13F filing for Q4 2022, filed 10 Feb 2023.